Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 197

Results For "SPE"

5007 News Found

Aster Health Academy to offer advanced medical courses
News | September 10, 2024

Aster Health Academy to offer advanced medical courses

The collaborations will help curate industry focused courses such as Advanced Certification courses for healthcare professionals in Healthcare Marketing, Healthcare Technology and Specialized Clinical Fellowship Level programs with university accreditation


Health Ministry releases
Policy | September 10, 2024

Health Ministry releases "Health Dynamics of India (Infrastructure and Human Resources) 2022-23"

The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions


Presence of Mpox virus of West African clade 2 confirmed in isolated patient
News | September 10, 2024

Presence of Mpox virus of West African clade 2 confirmed in isolated patient

This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards


Datopotamab deruxtecan showed median overall survival of 14.6 months in TROPION-Lung01 Phase III trial
Clinical Trials | September 10, 2024

Datopotamab deruxtecan showed median overall survival of 14.6 months in TROPION-Lung01 Phase III trial

TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population


Briefs: Ami Organics and Dr. Reddy’s Laboratories
Drug Approval | September 09, 2024

Briefs: Ami Organics and Dr. Reddy’s Laboratories

Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.


Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial
Clinical Trials | September 09, 2024

Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial

Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients


KIMS Hospitals, Hyderabad expands into Kerala
Healthcare | September 07, 2024

KIMS Hospitals, Hyderabad expands into Kerala

The company has entered into a long-term lease and operations and management agreement with Sree Chand Specialty Hospital, situated in Kannur


Nanoform and Celanese collaborate for biologics delivery through small implants
Biotech | September 07, 2024

Nanoform and Celanese collaborate for biologics delivery through small implants

The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics


Beiersdorf and Macro Biologics announce partnership to develop antimicrobial peptides
News | September 06, 2024

Beiersdorf and Macro Biologics announce partnership to develop antimicrobial peptides

Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare


Sun Pharma and Moebius Medical granted FTD to MM-II for treatment of osteoarthritis knee pain
Drug Approval | September 06, 2024

Sun Pharma and Moebius Medical granted FTD to MM-II for treatment of osteoarthritis knee pain

This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II